---
title: "Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292487461.md"
description: "Clearmind Medicine provided an update on its Phase I/IIa CMND-100 trial for alcohol use disorder. Investigators reported positive early impressions, successful recruitment, and no significant adverse events or cardiac safety concerns. The drug's non-hallucinogenic profile may facilitate a simpler outpatient treatment model."
datetime: "2026-07-13T12:18:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292487461.md)
  - [en](https://longbridge.com/en/news/292487461.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292487461.md)
generator: "portal-rs"
---

# Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insights

-   Clearmind Medicine published an update on early real-world insights from its ongoing first-in-human Phase I/IIa CMND-100 trial in alcohol use disorder. \* Investigators cited a generally positive early impression, citing recruitment progress and no meaningful adverse events or cardiac safety concerns to date. \* Update highlighted MEAI’s non-hallucinogenic profile as a potential enabler of a simpler outpatient treatment model. \* Webinar link: Watch the webinar here (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130817PRIMZONEFULLFEED9761076) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)

## Related News & Research

- [Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial](https://longbridge.com/en/news/295833036.md)
- [Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestone](https://longbridge.com/en/news/295791823.md)
- [Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint | CMND Stock News](https://longbridge.com/en/news/295792376.md)
- [Realheart targets February 2028 readiness for first-in-human implant of total artificial heart](https://longbridge.com/en/news/296444895.md)
- [How Investors Are Reacting To Medtronic (MDT) Cardiac Ablation Surge And Near-Dividend-King Milestone](https://longbridge.com/en/news/296452586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**